

Technology Appraisal Committee B Interests Register

Topic: trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]

Publication Date: 25 September 2024.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley	TAC B Committee Member	Direct - Financial Professional	In a previously treated CRC population but limited to HER2 positive population.	18/06/2024	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
David McAlister	TAC B Committee Member	Non-Financial Professional	David uses trial data provided by the sponsors or their competitors via the Vivli trial platform for academic research.	11/07/2024	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Peter Wheatley Price	TAC B Committee Member	Direct	Takeda manufacture fruquintinib which is currently in process for Fruquintinib for previously treated metastatic colorectal cancer ID6274. The scope is People with metastatic colorectal cancer (mCRC) who have had two or more previous treatments.	19/04/2024	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Whilst the comparators are not directly the same, I believe that the populations have significant overlap and that this then represents a commercial conflict of interest and I believe that this is too close or could be perceived as too close for me to participate		
David McAllister	TAC B Committee Member	Non-Financial Professional & Personal Interests	Work with data provided by sponsors or their competitors accessed via the Vivli trial data sharing platform.	28/05/2024	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Professor Mark Saunders	Clinical expert	Direct - Financial	Over the last 3 years Mark has received payment from Servier for lectures, meetings and to attend international meetings. Since April 2020, he has had 12 such meetings receiving £15,000. He received a fee for a talk for BAYER at UK Oncology Forum in June 23 (£1912.50).	15/05/2024	It was agreed that Professor Saunders' declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Harpreet Wasan	Clinical expert		<p>Over the last 20 years, Harpreet has been on advisory boards and has done educational development work and invited talks on colorectal cancer for many organisations including drugs recently approved in Colorectal cancer by NICE:</p> <p>Regorafenib (BAYER)</p> <p>Trifluridine-tipiracil (SERVIER)</p> <p>Encorafenib, Binimetinib and Cetuximab in BRAFV600E CRC (Array then Pfizer)</p> <p>In the last 12 months:</p> <p>Bayer (regorafenib). YES advisory board compensated</p> <p>Merck Serono (cetuximab). YES research- project development uncompensated</p> <p>Pierre Fabre (encorafenib). YES CRC manuscript in development uncompensated</p>	15/05/2024	It was agreed that Professor Wasan's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Pfizer (bevacizumab, irinotecan) YES encorafenib- Breakwater Global trial on steering committee / UK CI		